Analysts Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) PT at $63.67

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has received a consensus recommendation of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $63.67.

A number of equities research analysts have recently commented on TARS shares. Barclays cut their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. HC Wainwright reaffirmed a “buy” rating and set a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Guggenheim reaffirmed a “buy” rating and set a $78.00 price objective (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Oppenheimer increased their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Finally, Jefferies Financial Group increased their target price on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a “buy” rating in a report on Thursday, March 6th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in TARS. Lisanti Capital Growth LLC bought a new position in shares of Tarsus Pharmaceuticals in the third quarter worth about $1,311,000. GSA Capital Partners LLP bought a new position in shares of Tarsus Pharmaceuticals in the third quarter worth about $740,000. Mutual of America Capital Management LLC bought a new position in shares of Tarsus Pharmaceuticals in the third quarter worth about $4,291,000. Jennison Associates LLC raised its stake in shares of Tarsus Pharmaceuticals by 47.2% in the third quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock worth $71,653,000 after buying an additional 698,712 shares during the period. Finally, Intech Investment Management LLC bought a new position in shares of Tarsus Pharmaceuticals in the third quarter worth about $282,000. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Price Performance

Shares of Tarsus Pharmaceuticals stock opened at $48.09 on Friday. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The company has a market cap of $1.85 billion, a PE ratio of -12.62 and a beta of 1.05. The business has a 50 day moving average of $49.11 and a 200 day moving average of $44.59. Tarsus Pharmaceuticals has a 52 week low of $20.08 and a 52 week high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.08. The company had revenue of $66.41 million during the quarter, compared to the consensus estimate of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. As a group, equities research analysts forecast that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.